0 385

Cited 46 times in

Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy

DC Field Value Language
dc.contributor.author김진석-
dc.date.accessioned2018-05-10T06:32:33Z-
dc.date.available2018-05-10T06:32:33Z-
dc.date.issued2012-
dc.identifier.issn0020-7136-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/158152-
dc.description.abstractPrimary breast diffuse large B-cell lymphoma (DLBCL) is an extremely rare presentation of non-Hodgkin's lymphoma that has been associated with poorer clinical outcomes compared with nodal DLBCL in the pre-rituximab era. The aim of this study was to investigate the impact of rituximab on clinical outcomes in patients with primary breast DLBCL. Data from 25 female patients with primary breast DLBCL receiving rituximab plus chemotherapy were matched to 75 female patients (1:3) with nodal DLBCL by following five established prognostic factors (age, Ann Arbor stage, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase level and B symptoms). Overall survival (OS) was similar between primary breast and nodal DLBCL groups (3-year OS rate, 82.2% vs. 90.7%, respectively; p = 0.345). In the analysis of immunohistochemically defined prognostic subgroups, 19 of 20 available cases in the primary breast DLBCL group displayed a non-germinal center (GC) phenotype. Compared with patterns of recurrence, extranodal progression in the breast or central nervous system (CNS) was significantly higher in the primary breast DLBCL group than in the nodal DLBCL group (p < 0.001). Additionally, the stage-modified International Prognostic Index was the only independent prognostic factor for OS in this population. This suggests that clinical outcomes of primary breast DLBCL might no longer be inferior to those of nodal DLBCL in the rituximab era, which might be associated with the intrinsic biologic characteristics of the non-GC phenotype. However, despite including rituximab, extranodal progression in the breast or CNS was problematic. This study was registered at www.clinicaltrials.gov as no. NCT01266668.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-Liss-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntibodies, Monoclonal, Murine-Derived/therapeutic use*-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHBreast Neoplasms/drug therapy*-
dc.subject.MESHBreast Neoplasms/mortality-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHCyclophosphamide/therapeutic use-
dc.subject.MESHDisease Progression-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDoxorubicin/therapeutic use-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLymphoma, Large B-Cell, Diffuse/drug therapy*-
dc.subject.MESHLymphoma, Large B-Cell, Diffuse/mortality-
dc.subject.MESHLymphoma, Large B-Cell, Diffuse/pathology-
dc.subject.MESHMatched-Pair Analysis-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrednisone/therapeutic use-
dc.subject.MESHRituximab-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHVincristine/therapeutic use-
dc.subject.MESHYoung Adult-
dc.titleMatched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorHo-Young Yhim-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorHye Jin Kang-
dc.contributor.googleauthorSeok Jin Kim-
dc.contributor.googleauthorWon Seog Kim-
dc.contributor.googleauthorChul Won Choi-
dc.contributor.googleauthorHyeon Seok Eom-
dc.contributor.googleauthorJeong-A. Kim-
dc.contributor.googleauthorJae Hoon Lee-
dc.contributor.googleauthorJong Ho Won-
dc.contributor.googleauthorHyeok Shim-
dc.contributor.googleauthorJooryung Huh-
dc.contributor.googleauthorDae-Ho Lee-
dc.contributor.googleauthorCheolwon Suh-
dc.contributor.googleauthorJae-Yong Kwak-
dc.identifier.doi10.1002/ijc.26352-
dc.contributor.localIdA01017-
dc.relation.journalcodeJ01092-
dc.identifier.eissn1097-0215-
dc.identifier.pmid21823120-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1002/ijc.26352/abstract-
dc.subject.keywordbreast-
dc.subject.keywordcentral nervous system-
dc.subject.keyworddiffuse large B-cell lymphoma-
dc.subject.keywordrituximab-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.citation.volume131-
dc.citation.number1-
dc.citation.startPage235-
dc.citation.endPage243-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF CANCER, Vol.131(1) : 235-243, 2012-
dc.identifier.rimsid48915-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.